Metastatic Melanoma (Treat20Plus)
Treat20, was a pilot translational project designed to predict the drug response for 20 metastatic melanomas based on their molecular features and on the prediction of drug response (Christoph Wierling’s group). In Treat20, we analysed several melanoma types (cutaneous, uveal, iridal, mucosal and acrolentiginous), and found novel molecular events in non-UV induced, non-BRAF mutated melanomas, providing potential therapeutical targets. Treat20Plus, is a follow up project designe das a clinical trial for 35 metastatic melanomas refractory to treatment. The project is coordinated by ML Yaspo, in partnership with the CCCC, Charite (Prof. Ulrich Keilhoz) and Alacris Theranostics carrying out the tumor modeling for treatment recommendation.Our group will carry out the deep NGS analysis and will establish melanoma-derived microtissues, providing a platform for drug testing and model validation, but also a tool for investigating the interactions between melanoma cells and their stromal environment.